Skip to content

10x Genomics, Inc. TXG Ratios & Valuation

FY'25FY'24FY'23FY'22
Profitability
Gross margin69.1%+1.2pp67.9%+1.7pp66.2%-10.5pp76.7%-8.2pp
Operating margin-9.5%+22.4pp-31.9%+11.0pp-42.9%-10.4pp-32.5%-21.9pp
Net margin-6.8%+23.1pp-29.9%+11.3pp-41.2%-9.1pp-32.1%-20.3pp
EBITDA margin-3.9%+22.1pp-26%+11.2pp-37.1%-9.5pp-27.6%-21.3pp
Free cash flow margin20.2%-32%-7.0pp
Returns
Return on equity-5.8%+19.4pp-25.2%+7.8pp-33%-12.5pp-20.5%-13.0pp
Return on assets-4.4%+14.9pp-19.4%+6.2pp-25.6%-9.4pp-16.2%-10.2pp
Return on invested capital-14.3%+27.8pp-42%+4.1pp-46.1%-11.7pp-34.4%-9.3pp
Efficiency
Asset turnover0.7×0.0×0.6×0.0×0.6×+0.1×0.5×0.0×
Inventory turnover2.9×+0.3×2.5×-0.2×2.7×+1.0×1.7×+0.1×
Liquidity
Current ratio4.5×-0.5×+0.3×4.7×-0.2×4.8×-1.9×
Quick ratio4.1×-0.2×4.3×+0.2×4.1×-0.1×4.2×-2.0×
Cash ratio3.1×+0.2×2.9×+0.1×2.8×+1.1×1.7×-3.7×
Leverage
Debt-to-equity0.1×0.0×0.1×0.0×0.1×0.0×0.1×0.0×
Debt-to-assets0.1×0.0×0.1×0.0×0.1×0.0×0.1×0.0×
Per Share
Book value per share$6.38+8.3%$5.90-6.8%$6.32-10.6%$7.08-4.5%
Valuation
Market capitalization$2.06B+18.7%$1.74B-73.8%$6.63B+59.1%$4.17B-74.9%
Enterprise value$1.67B+13.4%$1.48B-76.8%$6.37B+57.7%$4.04B-75.0%
Price / sales3.2×+0.4×2.8×-7.9×10.7×+2.6×8.1×-25.8×
Price / book2.6×+0.1×2.4×-6.5×+3.8×5.2×-15.2×
EV / sales2.6×+0.2×2.4×-7.9×10.3×+2.5×7.8×-25.1×
Free cash flow yield6.3%-4%-3.2pp
Earnings yield-2.1%+8.4pp-10.5%-6.7pp-3.8%+0.1pp-4%-3.6pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are 10x Genomics, Inc.'s profit margins?
10x Genomics, Inc. (TXG) runs a 69.6% gross margin and a -6.1% operating margin, with a -3.5% net margin.
Where do 10x Genomics, Inc.'s ratios come from?
Every ratio is computed from 10x Genomics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.